Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.21.2
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Other Commitments [Line Items]            
Other receivable - related party $ 132,648   $ 132,648     $ 0
Research and development expense 2,664,979 $ 1,492,285 4,871,853 $ 2,105,362    
Technology Rights Agr [Member] | Houston Pharm [Member]            
Other Commitments [Line Items]            
Royalty income     175,000 100,000    
Wpd Product Supply Agr [Member] | Upfront Payment [Member]            
Other Commitments [Line Items]            
Other receivable - related party 131,073   131,073      
Wpd Product Supply Agr [Member] | Pass Thru Costs [Member]            
Other Commitments [Line Items]            
Other receivable - related party 1,575   1,575      
Patent And Technology License Agr [Member] | U T M D A C C [Member]            
Other Commitments [Line Items]            
License fee     22,902      
Contractual obligation $ 200,000   200,000      
Sponsored Research Agreement [Member] | U T M D A C C [Member]            
Other Commitments [Line Items]            
Contractual obligation   $ 734,000   $ 734,000    
Research and development expense     600,000      
Development Agreement [Member] | W P D [Member]            
Other Commitments [Line Items]            
Development Fees     $ 225,000      
Mr Climaco [Member]            
Other Commitments [Line Items]            
Salary and wages         $ 525,000  
Silberman [Member]            
Other Commitments [Line Items]            
Salary and wages         200,000  
Picker [Member]            
Other Commitments [Line Items]            
Salary and wages         115,000  
Mr Downs [Member]            
Other Commitments [Line Items]            
Salary and wages         $ 340,000